Adverse Effect Detected
During clinical studies of emicizumab (ACE910), a drug for treatment of severe hemophilia, four patients developed side effects. One of them developed thrombosis, the others had a condition leading to deposit of clots in capillaries and small arteries.
However, Roche, the company that developed the drug, is not going to discontinue the development with a large volume of investments. On the contrary, additional studies will be performed to find out the causes of adverse reaction.